Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Recordati Industria Chimica e Farmaceutica SpA
Gross Profit
Recordati Industria Chimica e Farmaceutica SpA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Gross Profit
€1.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Gross Profit
€50.5m
|
CAGR 3-Years
108%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Friulchem SpA
MIL:FCM
|
Gross Profit
€4.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Gross Profit
€35.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Recordati Industria Chimica e Farmaceutica SpA
Glance View
Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.
See Also
What is Recordati Industria Chimica e Farmaceutica SpA's Gross Profit?
Gross Profit
1.6B
EUR
Based on the financial report for Dec 31, 2024, Recordati Industria Chimica e Farmaceutica SpA's Gross Profit amounts to 1.6B EUR.
What is Recordati Industria Chimica e Farmaceutica SpA's Gross Profit growth rate?
Gross Profit CAGR 10Y
9%
Over the last year, the Gross Profit growth was 12%. The average annual Gross Profit growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 12% over the past three years , 9% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet